Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

In a situation as you described, I think

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
fsoalex Member Profile
 
Followed By 10
Posts 388
Boards Moderated 0
Alias Born 08/22/19
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 5:22:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 4:05:01 PM
CytoDyn reports leronlimab data in NASH trial for first 15 patients Seeking Alpha - 11/24/2021 10:08:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2021 5:24:15 PM
SA Breaking News - PURA estimates $1M in 2022 revenue InvestorsHub NewsWire - 11/22/2021 9:38:18 AM
PURA BULLISH RESURGANCE InvestorsHub NewsWire - 11/19/2021 8:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2021 6:02:41 AM
CytoDyn submits the first section of HIV BLA to FDA under rolling review Seeking Alpha - 11/16/2021 7:07:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:55:20 PM
CytoDyn submits leronlimab Breakthrough Therapy designation application to the FDA Seeking Alpha - 11/8/2021 7:50:43 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2021 11:30:49 AM
CytoDyn posts preliminary results from mid-stage leronlimab NASH study Seeking Alpha - 11/3/2021 6:11:13 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2021 2:06:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 1:58:46 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/27/2021 4:27:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/21/2021 4:10:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2021 4:07:39 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/20/2021 5:28:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2021 4:21:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2021 4:17:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2021 4:11:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2021 4:10:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2021 4:09:49 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/18/2021 4:22:29 PM
fsoalex   Tuesday, 07/21/20 07:41:15 PM
Re: humble howard post# 96863
Post # of 194966 
In a situation as you described, I think you also have to look at the people and companies surrounding Nader. Is the support from Amerek (sp?) up to par? Is the glacial pace of trials the norm in a time of pandemic? The PR and other PRs have not been as strong and precise as they should be. He needs a professional public relations assist. He over promises and under delivers constantly. He needs someone who will tell him clearly and precisely next steps and time frames. Is the Vyeera distribution company for the HIV use of Leronlimab strong enough. Dr Patterson and IncellDX should be the standard CytoDyn engages.
I have advocated previously that Nader needed more help on execution. Maybe the science advisory board will have the expertise to guide Nader to creating a better oiled machine. But after a working lifetime in planning and execution, I hear in your concerns and the angst of others on this board a plea that Cydy needs to be ready for the big leagues in the execution of the plan forward.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences